GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CV Sciences Inc (OTCPK:CVSI) » Definitions » Piotroski F-Score

CV Sciences (CV Sciences) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 2011. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

CV Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for CV Sciences's Piotroski F-Score or its related term are showing as below:

CVSI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of CV Sciences was 8. The lowest was 2. And the median was 3.


CV Sciences Piotroski F-Score Historical Data

The historical data trend for CV Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CV Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 3.00 3.00 7.00

CV Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 8.00 8.00 7.00

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where CV Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 5.706 + -1.288 + -0.447 + -0.869 = $3.10 Mil.
Cash Flow from Operations was 0.975 + 1.411 + -0.019 + -0.114 = $2.25 Mil.
Revenue was 4.148 + 3.966 + 4.089 + 3.801 = $16.00 Mil.
Gross Profit was 1.782 + 1.718 + 1.843 + 1.742 = $7.09 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(12.736 + 11.468 + 9.879 + 9.643 + 9.2) / 5 = $10.5852 Mil.
Total Assets at the begining of this year (Dec22) was $12.74 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Total Current Assets was $7.94 Mil.
Total Current Liabilities was $6.12 Mil.
Net Income was -2.217 + -2.653 + -1.031 + -2.313 = $-8.21 Mil.

Revenue was 4.447 + 4.138 + 3.751 + 3.869 = $16.21 Mil.
Gross Profit was 1.156 + 1.27 + 1.562 + 1.562 = $5.55 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(18.066 + 18.266 + 15.758 + 15.181 + 12.736) / 5 = $16.0014 Mil.
Total Assets at the begining of last year (Dec21) was $18.07 Mil.
Long-Term Debt & Capital Lease Obligation was $0.19 Mil.
Total Current Assets was $11.13 Mil.
Total Current Liabilities was $13.31 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

CV Sciences's current Net Income (TTM) was 3.10. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

CV Sciences's current Cash Flow from Operations (TTM) was 2.25. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=3.102/12.736
=0.24356156

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-8.214/18.066
=-0.45466622

CV Sciences's return on assets of this year was 0.24356156. CV Sciences's return on assets of last year was -0.45466622. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

CV Sciences's current Net Income (TTM) was 3.10. CV Sciences's current Cash Flow from Operations (TTM) was 2.25. ==> 2.25 <= 3.10 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.058/10.5852
=0.00547935

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.188/16.0014
=0.01174897

CV Sciences's gearing of this year was 0.00547935. CV Sciences's gearing of last year was 0.01174897. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=7.938/6.115
=1.29811938

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=11.13/13.314
=0.83596215

CV Sciences's current ratio of this year was 1.29811938. CV Sciences's current ratio of last year was 0.83596215. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

CV Sciences's number of shares in issue this year was 156.484. CV Sciences's number of shares in issue last year was 151.183. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7.085/16.004
=0.44270182

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5.55/16.205
=0.34248689

CV Sciences's gross margin of this year was 0.44270182. CV Sciences's gross margin of last year was 0.34248689. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=16.004/12.736
=1.25659548

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=16.205/18.066
=0.89698882

CV Sciences's asset turnover of this year was 1.25659548. CV Sciences's asset turnover of last year was 0.89698882. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

CV Sciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

CV Sciences  (OTCPK:CVSI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


CV Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of CV Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


CV Sciences (CV Sciences) Business Description

Traded in Other Exchanges
N/A
Address
9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, which are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). The company also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based novel therapeutics.
Executives
William Mccorkle director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Corroon James Michael Jr. director 9530 PADGETT STREET, SUITE 107, SAN DIEGO CA 92126
Maroon Joseph C Md director 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mona Michael Joseph Jr director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Paul Blake director 145 BRANDYWINE PKWY, WEST CHESTER PA 19380
Douglas Jesse Mackay officer: Sr VP Scientific/Regulatory 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Joseph D Dowling officer: Chief Financial Officer 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Joerg Grasser officer: CFO 2688 SOUTH RAINBOW BLVD STE B, LAS VEGAS NV 89146
Elizabeth Ann Altman director 10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Terri F Graham director C/O JACK IN THE BOX INC, 9330 BALVOA AVE, SAN DIEGO CA 92123
Stephen Martin Schmitz director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
Gary Sligar director 2688 SOUTH RAINBOW BOULEVARD, SUITE B, LAS VEGAS NV 89146
James A Mcnulty director C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Larry Phillip Raskin director 1630 FUNNY CIDE DRIVE, WAXHAW NC 28173
Mackay Ventures Inc. other: Member 10% holding group 6325 S. JONES BOULEVARD #500, LAS VEGAS NV 89118